Bart A. W. Jacobs

Bart A. W. Jacobs

Auto-generated profile, based on publicly available information

Bart A. W. Jacobs

Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YPYasmin Polak
Yasmin Polak
BJBart A. W. Jacobs
Bart A. W. Jacobs
EKE. Marleen Kemper
E. Marleen Kemper
Patients with rare diseases are often confronted with the fact that effective medicines are unavailable or simply not being developed. This situation jeopardizes the health of a large population of vulnerable patients with rare diseases. Pharmacy compounded formulations can provide a safe alternative when authorized treatments are unavailable or unsuitable. Practical guidelines on how to develop and implement pharmacy compounded formulations for patients with rare diseases are limited. The aim of this article is to provide guidance for when and how to apply pharmacy compounded formulations for patients with rare diseases. This is illustrated with two challenging examples: the development and implementation of pharmacy compounding of 1) chenodeoxycholic acid (CDCA) capsules for patients with cerebrotendinous xanthomatosis (CTX) and 2) cholic acid (CA) capsules for patients with rare bile acid synthesis defects (BASD). All critical steps of the development of CDCA and CA capsules are explained and summarized in a practical guideline.

15 January 2013 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
DPDick Pluim
Dick Pluim
BJBart A. W. Jacobs
Bart A. W. Jacobs
MKMartin D. Krähenbühl
Martin D. Krähenbühl
ARAnna E. M. Ruijter
Anna E. M. Ruijter
JBJos H. Beijnen
Jos H. Beijnen
JSJan H. M. Schellens
Jan H. M. Schellens

1 March 2024 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
CLCedric Lau
Cedric Lau
MAMa Ida Mohmaed Ali
Ma Ida Mohmaed Ali
LLLishi Lin
Lishi Lin
DBDorieke E. M. van Balen
Dorieke E. M. van Balen
BJBart A. W. Jacobs
Bart A. W. Jacobs
AHAlwin D. R. Huitema
Alwin D. R. Huitema
Purpose: The number of patients with bariatric surgery who receive oral anticancer drugs is rising. Bariatric surgery may affect the absorption of oral anticancer drugs. Strikingly, no specific drug dosing recommendations are available. We aim to provide practical recommendations on the application of oral anticancer drugs in patients who underwent bariatric surgery. Methods: Patients with any kind of bariatric surgery were extracted retrospectively in a comprehensive cancer center. In addition, a flowchart was proposed to assess the risk of inadequate exposure to oral anticancer drugs in patients who underwent bariatric surgery. Subsequently, the flowchart was evaluated retrospectively using routine Therapeutic drug monitoring (TDM) samples. Results: In our analysis, 571 cancer patients (0.4% of 140.000 treated or referred patients) had previous bariatric surgery. Of these patients, 78 unique patients received 152 oral anticancer drugs equaling an overall number of 30 unique drugs. The 30 different prescribed oral anticancer drugs were categorized as low risk (13%), medium risk (67%), and high risk (20%) of underdosing. TDM plasma samples of 25 patients (82 samples) were available, of which 21 samples post-bariatric surgery (25%) were below the target value. Conclusions: The proposed flowchart can support optimizing the treatment with orally administered anticancer drugs in patients who underwent bariatric surgery. We recommend performing TDM in drugs that belong to BCS classes II, III, or IV. If more risk factors are present in BCS classes II or IV, a priori switches to other drugs may be advised. In specific cases, higher dosages can be provided from the start (e.g., tamoxifen).

1 June 2026 in JCO Precision Oncology
Verified
Journal Article
Open access
NHNiels Heersche
Niels Heersche
JKJonathan E. Knikman
Jonathan E. Knikman
MDMaarten J. Deenen
Maarten J. Deenen
HRHilde Rosing
Hilde Rosing
RSRon H.N. Van Schaik
Ron H.N. Van Schaik
BJBart A.W. Jacobs
Bart A.W. Jacobs
PURPOSE: DPYD -guided fluoropyrimidine dosing effectively limits the risk of severe toxicity while maintaining clinical efficacy. However, recent data suggest that c.1236G>A variant carriers, starting with a 25% reduced dose, have shorter progression-free survival than wild-type patients receiving a full dose. Although overall survival was unaffected, further investigation is warranted. To address this, we retrospectively compared 5-fluorouracil (5-FU) exposure between c.1236G>A variant carriers and DPYD wild-type patients. MATERIALS AND METHODS: Pharmacokinetic data from nine clinical trials involving capecitabine-treated patients were pooled. Blood samples were collected before and after administration of capecitabine to assess systemic levels of its metabolites, including 5-FU. Capecitabine dosages were reduced for c.1236G>A variant carriers in accordance with the clinical guidelines at the time of study execution and varied from no reduction (n = 11) to a 25% (n = 16) or 50% (n = 8) reduction. Pharmacokinetic exposure, expressed as area under the plasma concentration-time curve (AUC 0-∞ ), was determined using noncompartmental analysis and dose-normalized to 850 mg/m 2 . RESULTS: In total, 35 heterozygous c.1236G>A patients and 66 DPYD wild-type patients were evaluable. Patients carrying c.1236G>A who received a 50% dose reduction had a lower dose-normalized geometric mean 5-FU exposure (234 ng·h/mL coefficient of variation [CV = 43%]) compared with fully dosed c.1236G>A carriers (553 ng·h/mL [CV = 51%]) and fully dosed DPYD wild-type patients (582 ng·h/mL [CV = 48%]; P < .001). All c.1236G>A carriers who received a 50% dose reduction had AUC 0-∞ values below the AUC 0-∞ range observed in the wild-type group. CONCLUSION: Our findings indicate that an upfront 25% dose reduction for capecitabine in c.1236G>A carriers is likely more appropriate than the currently recommended 50% dose reduction. We stress the importance of individual dose titration in c.1236G>A carriers to avoid both over- and undertreatment.

1 April 2026 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
MLMerel J. J. Lucassen
Merel J. J. Lucassen
PBPauline L. M. Buitelaar
Pauline L. M. Buitelaar
BJBart A. W. Jacobs
Bart A. W. Jacobs
TSTim Schutte
Tim Schutte
NSNeeltje Steeghs
Neeltje Steeghs
AHAlwin D. R. Huitema
Alwin D. R. Huitema
Over the last decade, there has been an increase in development of antibody drug conjugates (ADCs), a drug class designed to bring chemotherapeutic agents to tumour sites. The pharmacokinetics of ADCs are complex, due to their multifaceted structure consisting of an antibody linked to a (chemotherapeutic) payload. This review provides an overview of the pharmacokinetics of approved ADCs for patients with solid tumours in relation to toxicity and/or efficacy outcomes. Due to the complex nature and in vivo modifications of an ADC, the pharmacokinetic exposure is measured partially or with surrogate entities. These entities include the calculated drug-to-antibody ratio (DAR)-corrected ADC, measured conjugated antibody, total antibody and/or free payload concentration. A clear exposure-efficacy and exposure-toxicity relation was evident for the majority of ADCs. A higher exposure of almost all ADCs approved for patients with solid tumours, specifically the conjugated antibody entity, was related to higher objective response rates. A higher exposure of the free circulating cytotoxic payload and of the surrogate entities of ADC exposure, of ADCs with cleavable linkers, was related to toxicity. This is unsurprising as a higher circulating payload may induce toxicities associated with the related chemotherapeutic compound. Non-cleavable linkers increase the plasma stability compared to cleavable linkers, resulting in the absence of an (systemic) exposure-toxicity relation. The exposure-response relations for efficacy and toxicity seem apparent based on current literature, but quantification of all ADC components should be considered to fully elucidate the exposure-response relations. This is a crucial next step for dose optimisation and development of a new generation of this important new therapeutic class.

1 June 2021 in European Urology
Verified
Journal Article
Closed access
KRK. Van Renterghem
K. Van Renterghem
BJB. Jacobs
B. Jacobs
FYF. Yafi
F. Yafi
DOD. Osmonov
D. Osmonov
DRD. Ralph
D. Ralph
IMI. Mikoniatis
I. Mikoniatis